Farydak

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
0120152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Panobinostat (Farydak) is an orally active hydroxamic acid-derived histone deacetylase inhibitor used for the treatment of… (More)
  • table 1
  • table 2
  • table 4
  • table 5
  • table 6
Is this relevant?
Review
2016
Review
2016
PURPOSE The mechanism of action, pharmacodynamics, pharmacokinetics, clinical efficacy, interaction potential, adverse effects… (More)
Is this relevant?
2016
2016
Approved combination therapies A combination of the two HER2 (also known as ERBB2)-targeted drugs pertuzumab (Perjeta; Roche) and… (More)
  • table 1
  • figure 1
Is this relevant?
Review
2016
Review
2016
VOLUME 34 NUMBER 2 FEBRUARY 2016 NATURE BIOTECHNOLOGY on three types of approaches. One takes aim at the cell’s ability to… (More)
Is this relevant?
Review
2015
Review
2015
  • 2015
NEW DRUG APPROVALS Farydak for Multiple Myeloma The FDA has approved panobinostat (Farydak, Novartis) to treat multiple myeloma… (More)
Is this relevant?